CONVERGE Post-Approval Study (PAS) aims to check how well the EPi-Sense® device works for people with a heart rhythm problem called atrial fibrillation (AF). AF can make your heart beat irregularly and increase the chance of a stroke. This study focuses on people whose AF doesn't get better with certain heart medicines. The study will look at how well this device works over time and how safe it is when used by different doctors.

Eligibility: To join, you must be 18-79 years old, have a heart condition lasting over 12 months, and have tried certain medicines without success. You cannot participate if you need other heart surgeries or have certain health issues, like severe kidney problems or a history of heart surgery.

• The study will last several months and involve regular follow-ups.
• Participants may receive compensation for their time and effort.
• There are risks involved, including potential heart complications, so discuss with a doctor.

This study is important because it helps doctors decide the best ways to treat AF, especially for those with no other treatment options. If you think you might qualify, talk to your doctor to learn more about participating.